Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study.
OBJECTIVE
To evaluate the regional cerebral metabolic involvement; the relationships among regional brain metabolism, clinical features, and quantitative measures of disease severity; and the patterns of brain involvement that can be related to the different types of onset: striatonigral degeneration vs olivopontocerebellar atrophy.


METHODS
Fludeoxyglucose F 18 positron emission tomography (PET) studies performed in patients with multiple system atrophy (MSA) were evaluated for their clinical features at the onset of the disease and at the time of the PET study.


METHODS
Seventeen patients diagnosed as having probable MSA and 10 age-matched controls.


RESULTS
The hypometabolism in the putamen-pallidum complex and in the cerebellum was the best discriminant for disease classification. The efficacy of levodopa treatment was positively correlated with the metabolic activity of the putamen-pallidum complex. The patients with olivopontocerebellar atrophy type (N = 8) had a prevalent hypometabolism in the cerebellum, while the patients with striatonigral degeneration type (N = 9) had a prevalent impairment in the pallidum-putamen complex. We demonstrated a negative correlation between (1) severity of parkinsonism and metabolic values of putamen and caudate; (2) severity of cerebellar signs and metabolism in the cerebellum; and (3) autonomic dysfunction and metabolic activity in the thalamus, frontal, and temporal regions, bilaterally.


CONCLUSIONS
These findings support the selective metabolic reduction in the putamen and cerebellum as a marker of MSA. The clinical/metabolic correlations, demonstrating the expected dependence of extrapyramidal and cerebellar signs by dysfunction of basal ganglia and cerebellum, also support a possible involvement of central nervous system structures in autonomic control.
Perani
D
D
Institute of Neuroscience and Bioimaging, National Council of Research, Milan, Italy.
Bressi
S
S
Testa
D
D
Grassi
F
F
Cortelli
P
P
Gentrini
S
S
Savoiardo
M
M
Caraceni
T
T
Fazio
F
F
D001284:Atrophy; D001927:Brain Diseases / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D003847:Deoxyglucose / Q000031:analogs & derivatives; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009849:Olivopontocerebellar Atrophies / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D013378:Substantia Nigra / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D014055:Tomography, Emission-Computed
D019788:Fluorodeoxyglucose F18; D007980:Levodopa; D003847:Deoxyglucose; D005947:Glucose